Triptolide with Potential Medicinal Value for Diseases of the Central Nervous System

CNS Neuroscience and Therapeutics

Volumn 19, Issue 2, 2013, Pages 76-82

  Zheng, Yan ^a   Zhang, Wen Jing ^a   Wang, Xiao Min ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CNS diseases; Neurodegenerative diseases; Neuroprotection; Triptolide

Indexed keywords

12,13 CHLOROHYDRIN; 5 HYDROXYTRIPTOLIDE; ALPHA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROSTAGLANDIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN INJURY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG SOLUBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; INFERTILITY; MEDIAL FOREBRAIN BUNDLE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; REVIEW; SPERMATOGENESIS; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM DISEASES; DITERPENES; EPOXY COMPOUNDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHENANTHRENES; TRIPTERYGIUM;

EID: 84872685920     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12039     Document Type: Review

References (77)

1. Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991;34:1274-1281.
2. Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000;26:29-50, viii.
3. Kupchan SM, Court WA, Dailey RG Jr., Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972;94:7194-7195.
4. Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001;42:253-265.
5. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011;11:377-383.
6. Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 2012;29:457-475.
7. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 2007;68:732-766.
8. Yu DQ, Zhang DM, Wang HB, Liang XT. [Structure modification of triptolide, a diterpenoid from Tripterygium wilfordii]. Yao Xue Xue Bao 1992;27:830-836.
9. Zhou R, Zhang F, He PL, et al. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int Immunopharmacol 2005;5:1895-1903.
10. Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005;106:2409-2416.
11. Liu Q, Chen T, Chen G, et al. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 2007;44:2686-2696.
12. Wu C, Xia Y, Wang P, Lu L, Zhang F. Triptolide protects mice from ischemia/reperfusion injury by inhibition of IL-17 production. Int Immunopharmacol 2011;11:1564-1572.
13. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003;4:1-18.
14. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett 2010;292:149-152.
15. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17-22.
16. Amundson SA, Myers TG, Fornace AJ Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998;17:3287-3299.
17. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436.
18. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001;20:8009-8018.
19. Lin J, Chen LY, Lin ZX, Zhao ML. The effect of triptolide on apoptosis of glioblastoma multiforme (GBM) cells. J Int Med Res 2007;35:637-643.
20. Zhu W, Hu H, Qiu P, Yan G. Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. Oncol Rep 2009;22:1397-1401.
21. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat 2006;9:19-25.
22. Liu J, Jiang Z, Xiao J, et al. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine 2009;16:1006-1013.
23. Chang HJ, Kim MH, Baek MK, et al. Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells. Anticancer Res 2007;27:3411-3417.
24. Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology 2009;267:70-79.
25. Li J, Zhu W, Leng T, et al. Triptolide-induced cell cycle arrest and apoptosis in human renal cell carcinoma cells. Oncol Rep 2011;25:979-987.
26. Zhao F, Chen Y, Zeng L, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol 2010;646:1-11.
27. He MF, Huang YH, Wu LW, Ge W, Shaw PC, But PP. Triptolide functions as a potent angiogenesis inhibitor. Int J Cancer 2009;126:266-278.
28. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281:9616-9622.
29. Soundararajan R, Sayat R, Robertson GS, Marignani PA. Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol Ther 2009;8:2054-2062.
30. Mujumdar N, Mackenzie TN, Dudeja V, et al. Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 2010;139:598-608.
31. Vispe S, DeVries L, Creancier L, et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009;8:2780-2790.
32. Wang Y, Lu JJ, He L, Yu Q. Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS ONE 2011;6:e23993.
33. Titov DV, Gilman B, He QL, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011;7:182-188.
34. Zhen QS, Ye X, Wei ZJ. Recent progress in research on Tripterygium: a male antifertility plant. Contraception 1995;51:121-129.
35. Ji W, Li J, Lin Y, et al. Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii. Clin Rheumatol 2010;29:1067-1072.
36. Lue Y, Sinha Hikim AP, Wang C, et al. Triptolide: a potential male contraceptive. J Androl 1998;19:479-486.
37. Matlin SA, Belenguer A, Stacey VE, et al. Male antifertility compounds from Tripterygium wilfordii Hook f. Contraception 1993;47:387-400.
38. Huynh PN, Hikim AP, Wang C, et al. Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J Androl 2000;21:689-699.
39. Lu L, Li F, Wang X. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease. CNS Neurol Disord Drug Targets 2009;9:232-240.
40. Wang X, Liang XB, Li FQ, et al. Therapeutic strategies for Parkinson's disease: the ancient meets the future-traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells. Neurochem Res 2008;33:1956-1963.
41. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
42. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-393.
43. Li FQ, Cheng XX, Liang XB, et al. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol 2003;179:28-37.
44. Li FQ, Lu XZ, Liang XB, et al. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J Neuroimmunol 2004;148:24-31.
45. Zhou HF, Niu DB, Xue B, et al. Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. NeuroReport 2003;14:1091-1095.
46. Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM. Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol Dis 2005;18:441-449.
47. Gao JP, Sun S, Li WW, Chen YP, Cai DF. Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease. Neurosci Bull 2008;24:133-142.
48. Liu Y, Chen HL, Yang G. Extract of Tripterygium wilfordii Hook F protect dopaminergic neurons against lipopolysaccharide-induced inflammatory damage. Am J Chin Med 2010;38:801-814.
49. Li G, Ma R, Xu Y. [Protective effects of triptolide on the lipopolysaccharide-mediated degeneration of dopaminergic neurons in substantia nigra]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006;26:715-718.
50. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
51. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-1364.
52. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996;271:18295-18298.
53. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005;115:1121-1129.
54. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193-201.
55. Gu M, Zhou HF, Xue B, Niu DB, He QH, Wang XM. [Effect of Chinese herb Tripterygium wilfordii Hook F monomer triptolide on apoptosis of PC12 cells induced by Abeta1-42]. Sheng Li Xue Bao 2004;56:73-78.
56. He Q, Zhou H, Xue B, Niu D, Wang X. [Neuroprotective effects of Tripterygium Wilforddi Hook F monomer T10 on glutamate induced PC12 cell line damage and its mechanism]. Beijing Da Xue Xue Bao 2003;35:252-255.
57. Xue B, Jiao J, Zhang L, et al. Triptolide upregulates NGF synthesis in rat astrocyte cultures. Neurochem Res 2007;32:1113-1119.
58. Nie J, Zhou M, Lu C, et al. Effects of triptolide on the synaptophysin expression of hippocampal neurons in the AD cellular model. Int Immunopharmacol 2012;13:175-180.
59. Wei DM, Huang GZ, Zhang YG, Rao GX. [Influence of triptolide on neuronal apoptosis in rat with cerebral injury after focal ischemia reperfusion]. Zhongguo Zhong Yao Za Zhi 2004;29:1089-1091, 1116.
60. Lee HF, Lee TS, Kou YR. Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats. Respir Physiol Neurobiol 2012;182:1-8.
61. Su Z, Yuan Y, Cao L, et al. Triptolide promotes spinal cord repair by inhibiting astrogliosis and inflammation. Glia 2010;58:901-915.
62. Jadidi-Niaragh F, Mirshafiey A. Therapeutic approach to multiple sclerosis by novel oral drug. Recent Pat Inflamm Allergy Drug Discov 2010;5:66-80.
63. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-187.
64. Fu YF, Zhu YN, Ni J, et al. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J Neuroimmunol 2006;175:142-151.
65. Wang Y, Mei Y, Feng D, Xu L. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurosci Res 2008;86:2441-2449.
66. Kizelsztein P, Komarnytsky S, Raskin I. Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. J Neuroimmunol 2009;217:28-37.
67. Fan HC, Ren XR, Yu JZ, et al. [Suppression of murine EAE by triptolide is related to downregulation of INF-gamma and upregulation of IL-10 secretion in splenic lymphocytes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009;25:222-225.
68. van Eden W. Protective and therapeutic effect of triptolide in EAE explained by induction of major stress protein HSP70. J Neuroimmunol 2009;217:10-11.
69. Chan MA, Kohlmeier JE, Branden M, Jung M, Benedict SH. Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. Phytother Res 1999;13:464-467.
70. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999;274:13443-13450.
71. Gong Y, Xue B, Jiao J, Jing L, Wang X. Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 2008;107:779-788.
72. Geng Y, Fang M, Wang J, et al. Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and MAP kinases in lipopolysaccharide-treated PC12 cells. Phytother Res 2011;26:337-343.
73. Song JX, Sze SC, Ng TB, et al. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 2012;139:698-711.
74. Liu MX, Dong J, Yang YJ, Yang XL, Xu HB. [Preparation and toxicity of triptolide-loaded poly (D, L-lactic acid) nanoparticles]. Yao Xue Xue Bao 2004;39:556-560.
75. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003;56:189-196.
76. Mei Z, Li X, Wu Q, Hu S, Yang X. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacol Res 2005;51:345-351.
77. Mei Z, Wu Q, Hu S, Li X, Yang X. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Dev Ind Pharm 2005;31:161-168.